Home
Resources
Publications
Medroxyprogesterone Acetate Concentrations Among HIV-infected Depot-Medroxyprogesterone Acetate Users Receiving Antiretroviral Therapy in Lilongwe, Malawi

Medroxyprogesterone Acetate Concentrations Among HIV-infected Depot-Medroxyprogesterone Acetate Users Receiving Antiretroviral Therapy in Lilongwe, Malawi

Yasaman Zia, Jennifer H Tang, Lameck Chinula, Gerald Tegha, Frank Z Stanczyk, Athena P Kourtis

Contraception. 2019 Nov;100(5):402-405.

PMID: 31374188

Abstract:

Objective:
To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot medroxyprogesterone (DMPA) injectable.
Study design:
Secondary analysis of 28 HIV-positive women on non-nucleoside reverse transcriptase inhibitor-containing ART regimens and 10 HIV-negative women randomized to initiate DMPA in a clinical trial of progestin contraception in Malawi.
Results:
MPA concentrations were significantly lower among HIV-positive women on ART, compared with HIV-negative women, at week 4 and week 13 (p=.03 for both), but not at day 3 or week 26 post-DMPA initiation.
Conclusions:
Antiretroviral medications may affect MPA metabolism in HIV-positive African women.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP71589-B	Medroxyprogesterone Acetate		71-58-9	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: